LAG-3 inhibitor
/ Arcus Biosciences
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 19, 2022
Expert Explains Rationale Behind RELATIVITY-047 in Melanoma
(Oncology Nursing News)
- P2/3, N=714; RELATIVITY-047 (NCT03470922); Sponsor: Bristol-Myers Squibb; Dr. Hussein Tawbi, MD, PhD, explains the rationale behind the RELATIVITY-047 trial in melanoma and how the LAG-3 findings could further revolutionize immunotherapy."
Interview • P2/3 data
1 to 1
Of
1
Go to page
1